249 related articles for article (PubMed ID: 19414675)
21. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.
Carlring J; Szabo MJ; Dickinson R; De Leenheer E; Heath AW
Blood; 2012 Mar; 119(9):2056-65. PubMed ID: 22234700
[TBL] [Abstract][Full Text] [Related]
22. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966
[No Abstract] [Full Text] [Related]
23. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
Lawson DH; Lee S; Zhao F; Tarhini AA; Margolin KA; Ernstoff MS; Atkins MB; Cohen GI; Whiteside TL; Butterfield LH; Kirkwood JM
J Clin Oncol; 2015 Dec; 33(34):4066-76. PubMed ID: 26351350
[TBL] [Abstract][Full Text] [Related]
24. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W
Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420
[TBL] [Abstract][Full Text] [Related]
25. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Gordon LI; Witzig T; Molina A; Czuczman M; Emmanouilides C; Joyce R; Vo K; Theuer C; Pohlman B; Bartlett N; Wiseman G; Darif M; White C
Clin Lymphoma; 2004 Sep; 5(2):98-101. PubMed ID: 15453924
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
27. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
[TBL] [Abstract][Full Text] [Related]
28. Immune responses and outcome in follicular lymphoma.
Gribben JG
J Clin Oncol; 2014 Jun; 32(17):1757-9. PubMed ID: 24799493
[No Abstract] [Full Text] [Related]
29. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
[TBL] [Abstract][Full Text] [Related]
30. Evaluation on a six-dose treatment of anti CD 20 monoclonal antibody in patients with refractory follicular lymphoma.
Avilés A; Talavera A; Díaz-Maqueo JC; García EL; Cleto S; Neri N
Cancer Biother Radiopharm; 2001 Apr; 16(2):159-62. PubMed ID: 11385962
[TBL] [Abstract][Full Text] [Related]
31. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
32. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
[TBL] [Abstract][Full Text] [Related]
33. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
34. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
35. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.
Huhn D; von Schilling C; Wilhelm M; Ho AD; Hallek M; Kuse R; Knauf W; Riedel U; Hinke A; Srock S; Serke S; Peschel C; Emmerich B;
Blood; 2001 Sep; 98(5):1326-31. PubMed ID: 11520778
[TBL] [Abstract][Full Text] [Related]
36. Prolonged idiotypic vaccination against follicular lymphoma.
Inoges S; Lopez-Diaz de Cerio A; Zabalegui N; Soria E; Villanueva H; Panizo C; Rodriguez-Caballero A; Suarez L; Pastor F; Rodriguez-Calvillo M; Orfao A; Bendandi M
Leuk Lymphoma; 2009 Jan; 50(1):47-53. PubMed ID: 19152172
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
Redfern CH; Guthrie TH; Bessudo A; Densmore JJ; Holman PR; Janakiraman N; Leonard JP; Levy RL; Just RG; Smith MR; Rosenfelt FP; Wiernik PH; Carter WD; Gold DP; Melink TJ; Gutheil JC; Bender JF
J Clin Oncol; 2006 Jul; 24(19):3107-12. PubMed ID: 16754937
[TBL] [Abstract][Full Text] [Related]
38. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma.
Kolstad A; Kumari S; Walczak M; Madsbu U; Hagtvedt T; Bogsrud TV; Kvalheim G; Holte H; Aurlien E; Delabie J; Tierens A; Olweus J
Blood; 2015 Jan; 125(1):82-9. PubMed ID: 25293773
[TBL] [Abstract][Full Text] [Related]
39. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
40. Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.
Cox MC; Castiello L; Mattei M; Santodonato L; D'Agostino G; Muraro E; Martorelli D; Lapenta C; Di Napoli A; Di Landro F; Cangemi M; Pavan A; Castaldo P; Hohaus S; Donati S; Montefiore E; Berdini C; Carlei D; Monque DM; Ruco L; Prosperi D; Tafuri A; Spadaro F; Sestili P; Spada M; Dolcetti R; Santini SM; Rozera C; Aricò E; Capone I; Belardelli F
Clin Cancer Res; 2019 Sep; 25(17):5231-5241. PubMed ID: 31171545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
